Share
Explore

Gene Therapy Market Share and Key Players are Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), and others

The global research report, recently added by Value Market Research, is entailed of various market parameters including market outlook, share, trends, growth, value and factors that are currently influencing the market dynamics. The report discloses forecast for the period 2021-2028 based on the historical data. Additionally, this report also maps the recent strategic developments of key players along with their market share.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gene therapy market include Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Italy), Orchard Therapeutics plc. (UK), Sibiono GeneTech Co. Ltd. (China), Alnylam Pharmaceuticals, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Dynavax Technologies (US), Jazz Pharmaceuticals, Inc. (Ireland), and Akcea Therapeutics (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
The growing field of advanced therapies and gene delivery technologies has spawned a competitive environment in which a large number of market players are attempting to commercialize their gene therapy products. Although the high prices of currently available therapies encourage more development in this field, but are also responsible for limiting the accessibility and may lead to market withdrawals due to the lack of economic viability. Biopharma companies have taken a number of steps to gain a competitive advantage in the market. Companies are pursuing various market entry strategies, including expanding biopharmaceutical facilities, collaborating with other key stakeholders, and developing products with Contract Manufacturing Organizations (CMOs).
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gene therapy. The growth and trends of gene therapy industry provide a holistic approach to this study.
This section of the gene therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Vector
· Non-Viral Vectors (Oligonucleotides, Other Non-Viral Vectors (Plasmids And RNAi))
· Viral Vectors (Retroviral Vectors, Gammaretroviral Vectors, Lentiviral Vectors, Adeno-Associated Virus Vectors, Other Viral Vectors (Herpes Simplex And Adenoviral Vectors))
By Indication
· Neurological Diseases
· Cancer
· Duchenne Muscular Dystrophy
· Hepatological Diseases
· Other Indications (Retinal Diseases, Beta-Thalassemia, Peripheral Artery Disease, And Immune Deficiency Diseases)
By Delivery Method
· In Vivo
· Ex Vivo
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Gene Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Browse Global Gene Therapy Market Research Report with detailed TOC at
Want to print your doc?
This is not the way.
Try clicking the ⋯ next to your doc name or using a keyboard shortcut (
CtrlP
) instead.